UroGen Pharma Releases Long-Term Cancer Study Results
Final data from the Olympus clinical study confirms durable responses for patients with upper tract urothelial cancer.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you trust non-surgical drug therapies as a reliable long-term alternative to traditional cancer surgery?
UroGen Pharma has published final five-year results from its Olympus clinical study on JELMYTO. The data highlights a durable treatment response in patients with low-grade upper tract urothelial cancer.
Why it matters
These long-term findings demonstrate the potential for JELMYTO to provide sustained disease control for patients. The study results offer significant insights into the efficacy of the therapy over an extended period.
The Olympus study recorded a median duration of response of 47.8 months among 41 patients who achieved a complete response. Additionally, 75% of the 20 patients in the long-term follow-up study remained event-free as of March 2025.
The players
UroGen Pharma
A biotechnology company headquartered in Princeton that specializes in developing treatments for urological cancers.
The details
JELMYTO is administered as a retrograde solution or via a nephrostomy tube, utilizing a liquid-to-gel transition at body temperature. The study observed no progression to high-grade disease during the extended five-year follow-up period.
Timeline
March 2025 marked the period where 75% of long-term patients were event-free.
October 28, 2026, was the date of the final Olympus study results publication.
The Big Picture
The publication concludes the long-term follow-up phase of the Olympus clinical study. This data establishes a new benchmark for durable treatment response in patients with upper tract urothelial cancer.
These findings indicate that patients treated with JELMYTO may experience extended periods of disease control without progression to high-grade cancer. Individuals should consult with their healthcare providers regarding the suitability of this therapy based on these study results.
The takeaway
The sustained success rate seen in these five-year results underscores the importance of long-term monitoring for cancer patients. Patients and providers can use this data to better understand the potential duration of treatment responses for this specific condition.
What happens next
UroGen Pharma expects to receive real-world data regarding the use of JELMYTO from the uTRACT Registry.
Further reading
For more information on similar research, visit the Cancer section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust non-surgical drug therapies as a reliable long-term alternative to traditional cancer surgery?
